NeoGenomics, Inc. Operating Lease Cost
NeoGenomics, Inc. (NEO) reported Operating Lease Cost of $9.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-17
- NeoGenomics, Inc. operating lease, cost for the quarter ending 2021-12-31 was $3.34M, a 42.44% increase year-over-year.
- NeoGenomics, Inc. operating lease, cost for the quarter ending 2021-09-30 was $3.21M, a 83.80% increase year-over-year.
- NeoGenomics, Inc. operating lease, cost for the quarter ending 2021-06-30 was $2.37M, a 9.21% increase year-over-year.
- NeoGenomics, Inc. operating lease, cost for the quarter ending 2021-03-31 was $2.31M, a 9.50% increase year-over-year.
- NeoGenomics, Inc. operating lease, cost for fiscal 2025 was $9.55M, a 18.58% decline from fiscal 2024.
- NeoGenomics, Inc. operating lease, cost for fiscal 2024 was $11.73M, a 2.44% decline from fiscal 2023.
- NeoGenomics, Inc. operating lease, cost for fiscal 2023 was $12.03M, a 8.45% decline from fiscal 2022.
- NeoGenomics, Inc. operating lease, cost for fiscal 2022 was $13.13M, a 16.95% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.55M 10-K · filed 2026-02-17 | |||
| 2024-12-31 | $11.73M 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $12.03M 10-K · filed 2025-02-18 | |||
| 2022-12-31 | $13.13M 10-K · filed 2024-02-20 | |||
| 2021-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $6.55M derived: sum of 2 quarters · filed 2023-02-24 | $8.93M derived: sum of 3 quarters · filed 2023-02-24 | $11.23M 10-K · filed 2023-02-24 |
| 2021-09-30 | $3.21M 10-Q · filed 2021-11-04 | $5.58M derived: sum of 2 quarters · filed 2021-11-04 | $7.89M 10-Q · filed 2021-11-04 | $10.23M derived: sum of 4 quarters · filed 2022-02-25 |
| 2021-06-30 | $2.37M 10-Q · filed 2021-08-09 | $4.68M 10-Q · filed 2021-08-09 | $7.02M derived: sum of 3 quarters · filed 2022-02-25 | $8.77M derived: sum of 4 quarters · filed 2022-02-25 |
| 2021-03-31 | $2.31M 10-Q · filed 2021-05-06 | $4.65M derived: sum of 2 quarters · filed 2022-02-25 | $6.40M derived: sum of 3 quarters · filed 2022-02-25 | $8.57M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $4.09M derived: sum of 2 quarters · filed 2022-02-25 | $6.27M derived: sum of 3 quarters · filed 2022-02-25 | $8.37M 10-K · filed 2022-02-25 |
| 2020-09-30 | $1.75M 10-Q · filed 2021-11-04 | $3.92M derived: sum of 2 quarters · filed 2021-11-04 | $6.02M 10-Q · filed 2021-11-04 | $7.72M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $2.17M 10-Q · filed 2021-08-09 | $4.28M 10-Q · filed 2021-08-09 | $5.97M derived: sum of 3 quarters · filed 2021-08-09 | $7.24M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $2.10M 10-Q · filed 2021-05-06 | $3.80M derived: sum of 2 quarters · filed 2021-05-06 | $5.07M derived: sum of 3 quarters · filed 2021-05-06 | $6.62M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.97M derived: sum of 2 quarters · filed 2021-02-25 | $4.51M derived: sum of 3 quarters · filed 2021-02-25 | $6.06M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.27M 10-Q · filed 2020-10-29 | $2.82M derived: sum of 2 quarters · filed 2020-10-29 | $4.37M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $1.55M 10-Q · filed 2020-07-31 | $3.09M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $1.50M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |